Keene & Associates Inc. Boosts Stock Holdings in Haemonetics Co. (NYSE:HAE)

Keene & Associates Inc. boosted its holdings in Haemonetics Co. (NYSE:HAE) by 3.0% during the 3rd quarter, HoldingsChannel.com reports. The fund owned 10,174 shares of the medical instruments supplier’s stock after buying an additional 298 shares during the period. Keene & Associates Inc.’s holdings in Haemonetics were worth $818,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in HAE. Capital Research Global Investors raised its stake in shares of Haemonetics by 2.3% in the first quarter. Capital Research Global Investors now owns 6,674,751 shares of the medical instruments supplier’s stock worth $569,690,000 after purchasing an additional 151,183 shares during the last quarter. Vanguard Group Inc. raised its position in Haemonetics by 0.5% in the 4th quarter. Vanguard Group Inc. now owns 5,406,309 shares of the medical instruments supplier’s stock worth $462,293,000 after buying an additional 25,451 shares during the last quarter. Dimensional Fund Advisors LP raised its position in Haemonetics by 6.3% in the 2nd quarter. Dimensional Fund Advisors LP now owns 978,735 shares of the medical instruments supplier’s stock worth $80,972,000 after buying an additional 57,665 shares during the last quarter. Thrivent Financial for Lutherans lifted its stake in Haemonetics by 6,573.6% during the 2nd quarter. Thrivent Financial for Lutherans now owns 849,350 shares of the medical instruments supplier’s stock valued at $70,267,000 after acquiring an additional 836,623 shares during the period. Finally, Allspring Global Investments Holdings LLC boosted its holdings in shares of Haemonetics by 75.9% during the 3rd quarter. Allspring Global Investments Holdings LLC now owns 795,381 shares of the medical instruments supplier’s stock valued at $63,933,000 after acquiring an additional 343,214 shares during the last quarter. 99.67% of the stock is owned by institutional investors.

Haemonetics Stock Performance

Shares of HAE opened at $73.29 on Thursday. The business has a 50-day simple moving average of $75.67 and a two-hundred day simple moving average of $83.35. The company has a quick ratio of 2.33, a current ratio of 3.76 and a debt-to-equity ratio of 1.35. Haemonetics Co. has a 52 week low of $70.74 and a 52 week high of $97.97. The stock has a market cap of $3.73 billion, a price-to-earnings ratio of 32.00, a PEG ratio of 1.19 and a beta of 0.30.

Haemonetics (NYSE:HAE) last released its earnings results on Thursday, August 8th. The medical instruments supplier reported $1.02 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.03 by ($0.01). Haemonetics had a return on equity of 21.86% and a net margin of 8.61%. The firm had revenue of $336.17 million during the quarter, compared to analysts’ expectations of $335.08 million. During the same period in the prior year, the company posted $1.05 earnings per share. The company’s revenue was up 8.0% compared to the same quarter last year. On average, analysts expect that Haemonetics Co. will post 4.57 EPS for the current year.

Insider Transactions at Haemonetics

In related news, insider Stewart W. Strong sold 4,312 shares of Haemonetics stock in a transaction on Friday, July 26th. The shares were sold at an average price of $91.15, for a total transaction of $393,038.80. Following the transaction, the insider now owns 18,196 shares in the company, valued at approximately $1,658,565.40. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Corporate insiders own 1.80% of the company’s stock.

Analysts Set New Price Targets

Several research analysts have recently weighed in on HAE shares. BTIG Research assumed coverage on shares of Haemonetics in a report on Tuesday, September 10th. They set a “buy” rating and a $112.00 price objective for the company. CL King initiated coverage on shares of Haemonetics in a research note on Friday, September 13th. They set a “buy” rating and a $116.00 target price for the company. Barrington Research reissued an “outperform” rating and set a $108.00 price target on shares of Haemonetics in a report on Monday, September 23rd. JMP Securities reaffirmed a “market outperform” rating and issued a $125.00 price objective on shares of Haemonetics in a report on Tuesday, August 13th. Finally, Bank of America assumed coverage on Haemonetics in a research report on Wednesday, September 11th. They set a “neutral” rating and a $85.00 price objective for the company. Three analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $106.14.

About Haemonetics

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.